{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:41:16Z","timestamp":1792690876186,"version":"4.5.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci. China Life Sci."],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s11427-026-3437-0","type":"journal-article","created":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T02:45:14Z","timestamp":1784342714000},"page":"3868-3885","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["5-FU chemotherapy induces functional CD7+ and IL7R+ CTLs infiltration to suppress colorectal tumor progression"],"prefix":"10.1007","volume":"69","author":[{"given":"Yanmin","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufeng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunwan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"3437_CR1","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.4049\/jimmunol.170.5.2349","volume":"170","author":"EM Aandahl","year":"2003","unstructured":"Aandahl, E.M., Sandberg, J.K., Beckerman, K.P., Task\u00e9n, K., Moretto, W.J., and Nixon, D.F. (2003). CD7 is a differentiation marker that identifies multiple CD8 T cell effector subsets. J Immunol 170, 2349\u20132355.","journal-title":"J Immunol"},{"key":"3437_CR2","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9, T., Shiu, K.K., Kim, T.W., Jensen, B.V., Jensen, L.H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020). Pembrolizumab in microsatellite-instability\u2014high advanced colorectal cancer. N Engl J Med 383, 2207\u20132218.","journal-title":"N Engl J Med"},{"key":"3437_CR3","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1182\/blood-2008-07-166223","volume":"113","author":"RI Azevedo","year":"2009","unstructured":"Azevedo, R.I., Soares, M.V.D., Barata, J.T., Tendeiro, R., Serra-Caetano, A., Victorino, R.M.M., and Sousa, A.E. (2009). IL-7 sustains CD31 expression in human naive CD4+ T cells and preferentially expands the CD31+ subset in a PI3K-dependent manner. Blood 113, 2999\u20133007.","journal-title":"Blood"},{"key":"3437_CR4","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3390\/biology10090854","volume":"10","author":"S Azwar","year":"2021","unstructured":"Azwar, S., Seow, H.F., Abdullah, M., Faisal Jabar, M., and Mohtarrudin, N. (2021). Recent updates on mechanisms of resistance to 5-fluorouracil and reversal strategies in colon cancer treatment. Biology 10, 854.","journal-title":"Biology"},{"key":"3437_CR5","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1136\/gutjnl-2018-316191","volume":"68","author":"AM Baker","year":"2019","unstructured":"Baker, A.M., Cross, W., Curtius, K., Al Bakir, I., Choi, C.H.R., Davis, H.L., Temko, D., Biswas, S., Martinez, P., Williams, M.J., et al. (2019). Evolutionary history of human colitis-associated colorectal cancer. Gut 68, 985\u2013995.","journal-title":"Gut"},{"key":"3437_CR6","first-page":"e240029","volume":"22","author":"AB Benson","year":"2024","unstructured":"Benson, A.B., Venook, A.P., Adam, M., Chang, G., Chen, Y.J., Ciombor, K.K., Cohen, S. A., Cooper, H.S., Deming, D., Garrido-Laguna, I., et al. (2024). Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 22, e240029.","journal-title":"J Natl Compr Cancer Netw"},{"key":"3437_CR7","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.3390\/cancers17142303","volume":"17","author":"A Bhadran","year":"2025","unstructured":"Bhadran, A., Polara, H., Babanyinah, G.K., Baburaj, S., and Stefan, M.C. (2025). Advances in doxorubicin chemotherapy: emerging polymeric nanocarriers for drug loading and delivery. Cancers 17, 2303.","journal-title":"Cancers"},{"key":"3437_CR8","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J.R., Tykodi, S.S., Chow, L.Q.M., Hwu, W.J., Topalian, S.L., Hwu, P., Drake, C.G., Camacho, L.H., Kauh, J., Odunsi, K., et al. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366, 2455\u20132465.","journal-title":"N Engl J Med"},{"key":"3437_CR9","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.ccell.2017.11.004","volume":"32","author":"\u00d6 Canli","year":"2017","unstructured":"Canli, \u00d6., Nicolas, A.M., Gupta, J., Finkelmeier, F., Goncharova, O., Pesic, M., Neumann, T., Horst, D., L\u00f6wer, M., Sahin, U., et al. (2017). Myeloid cell-derived reactive oxygen species induce epithelial mutagenesis. Cancer Cell 32, 869\u2013883.e5.","journal-title":"Cancer Cell"},{"key":"3437_CR10","doi-asserted-by":"publisher","first-page":"108514","DOI":"10.4251\/wjgo.v17.i10.108514","volume":"17","author":"M Catalano","year":"2025","unstructured":"Catalano, M., Mini, E., Nobili, S., Vascotto, I.A., Ravizza, D., Amorosi, A., Tonelli, F., Roviello, F., Roviello, G., and Nesi, G. (2025). Ulcerative colitis and colorectal cancer: pathogenic insights and precision strategies for prevention and treatment. World J Gastrointest Oncol 17, 108514.","journal-title":"World J Gastrointest Oncol"},{"key":"3437_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","volume":"34","author":"A Cervantes","year":"2023","unstructured":"Cervantes, A., Adam, R., Rosell\u00f3, S., Arnold, D., Normanno, N., Ta\u00efeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023). Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34, 10\u201332.","journal-title":"Ann Oncol"},{"key":"3437_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12929-025-01154-6","volume":"32","author":"YC Chang","year":"2025","unstructured":"Chang, Y.C., Chen, S.J., Chen, S.H., Hsiao, S.Y., Chen, L.H., Chen, C.H., Liu, C.C., Chen, Y.W., Liu, K.J., Wu, S.Y., et al. (2025). Unraveling Cathepsin S regulation in interleukin-7-mediated anti-tumor immunity reveals its targeting potential against oral cancer. J Biomed Sci 32, 69.","journal-title":"J Biomed Sci"},{"key":"3437_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41392-022-00898-z","volume":"7","author":"Z Dai","year":"2022","unstructured":"Dai, Z., Mu, W., Zhao, Y., Cheng, J., Lin, H., Ouyang, K., Jia, X., Liu, J., Wei, Q., Wang, M., et al. (2022). T cells expressing CD5\/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape. Sig Transduct Target Ther 7, 85.","journal-title":"Sig Transduct Target Ther"},{"key":"3437_CR14","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","volume":"23","author":"LA Diaz Jr.","year":"2022","unstructured":"Diaz Jr., L.A., Shiu, K.K., Kim, T.W., Jensen, B.V., Jensen, L.H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2022). Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol 23, 659\u2013670.","journal-title":"Lancet Oncol"},{"key":"3437_CR15","doi-asserted-by":"publisher","first-page":"4862706","DOI":"10.1155\/2024\/4862706","volume":"1","author":"I El-Serafi","year":"2024","unstructured":"El-Serafi, I., Steele, S., and Mudigonda, K. (2024). Cyclophosphamide pharmacogenomic variation in cancer treatment and its effect on bioactivation and pharmacokinetics. Adv Pharmacol Pharm Sci 1, 4862706.","journal-title":"Adv Pharmacol Pharm Sci"},{"key":"3437_CR16","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1182\/blood.2021015020","volume":"140","author":"A Freiwan","year":"2022","unstructured":"Freiwan, A., Zoine, J.T., Crawford, J.C., Vaidya, A., Schattgen, S.A., Myers, J.A., Patil, S.L., Khanlari, M., Inaba, H., Klco, J.M., et al. (2022). Engineering naturally occurring CD7\u2212 T cells for the immunotherapy of hematological malignancies. Blood 140, 2684\u20132696.","journal-title":"Blood"},{"key":"3437_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/pros.24830","volume":"85","author":"E He","year":"2025","unstructured":"He, E., Li, Y., Zhao, R., Kong, Q., Shao, Y., Wang, C., Liu, B., Jiang, Y., Liu, Q., and Cui, H. (2025). IL7 as a risk factor for prostate cancer: implications for T cell apoptosis and infiltration in the tumor microenvironment. Prostate 85, 315\u2013323.","journal-title":"Prostate"},{"key":"3437_CR18","doi-asserted-by":"publisher","first-page":"e000586","DOI":"10.1136\/jitc-2020-000586","volume":"8","author":"DP Hurkmans","year":"2020","unstructured":"Hurkmans, D.P., Basak, E.A., Schepers, N., Oomen-De Hoop, E., Van der Leest, C.H., El Bouazzaoui, S., Bins, S., Koolen, S.L.W., Sleijfer, S., Van der Veldt, A.A.M., et al. (2020). Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer. J Immunother Cancer 8, e000586.","journal-title":"J Immunother Cancer"},{"key":"3437_CR19","doi-asserted-by":"publisher","first-page":"116316","DOI":"10.1016\/j.celrep.2025.116316","volume":"44","author":"S Hyslop","year":"2025","unstructured":"Hyslop, S., Hofferek, C.J., Stegantseva, M.V., Kan, E., McCord, K.A., Alvarez, V.M., Xia, A.Y., Conarty, J.P., Wieland, A., and Hudson, W.H. (2025). CD7 regulates the persistence of terminally exhausted CD8+ T cells during chronic infection. Cell Rep 44, 116316.","journal-title":"Cell Rep"},{"key":"3437_CR20","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1016\/j.celrep.2018.11.050","volume":"25","author":"ML Ibrahim","year":"2018","unstructured":"Ibrahim, M.L., Klement, J.D., Lu, C., Redd, P.S., Xiao, W., Yang, D., Browning, D.D., Savage, N.M., Buckhaults, P.J., Morse III, H.C., et al. (2018). Myeloid-derived suppressor cells produce IL-10 to elicit DNMT3b-dependent IRF8 silencing to promote colitis-associated colon tumorigenesis. Cell Rep 25, 3036\u20133046.e6.","journal-title":"Cell Rep"},{"key":"3437_CR21","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.4049\/jimmunol.1501657","volume":"195","author":"S Ilyas","year":"2015","unstructured":"Ilyas, S., and Yang, J.C. (2015). Landscape of tumor antigens in T cell immunotherapy. J Immunol 195, 5117\u20135122.","journal-title":"J Immunol"},{"key":"3437_CR22","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1158\/1078-0432.CCR-06-2890","volume":"13","author":"J Ju","year":"2007","unstructured":"Ju, J., Schmitz, J.C., Song, B., Kudo, K., and Chu, E. (2007). Regulation of p53 expression in response to 5-fluorouracil in human cancer RKO cells. Clin Cancer Res 13, 4245\u20134251.","journal-title":"Clin Cancer Res"},{"key":"3437_CR23","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","volume":"12","author":"GD Kalliolias","year":"2016","unstructured":"Kalliolias, G.D., and Ivashkiv, L.B. (2016). TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol 12, 49\u201362.","journal-title":"Nat Rev Rheumatol"},{"key":"3437_CR24","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A. D., Luber, B.S., Azad, N.S., Laheru, D., et al. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372, 2509\u20132520.","journal-title":"N Engl J Med"},{"key":"3437_CR25","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1186\/s12885-024-12742-4","volume":"24","author":"X Li","year":"2024","unstructured":"Li, X., Chen, Y., Liang, Y., and Shi, W. (2024). 5-Fluorouracil resistance due to sphingosine kinase 2 overexpression in colorectal cancer is associated with myeloid-derived suppressor cell-mediated immunosuppressive effects. BMC Cancer 24, 983.","journal-title":"BMC Cancer"},{"key":"3437_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","volume":"5","author":"NJ Llosa","year":"2015","unstructured":"Llosa, N.J., Cruise, M., Tam, A., Wicks, E.C., Hechenbleikner, E.M., Taube, J.M., Blosser, R.L., Fan, H., Wang, H., Luber, B.S., et al. (2015). The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 5, 43\u201351.","journal-title":"Cancer Discov"},{"key":"3437_CR27","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley, D.B., Harkin, D.P., and Johnston, P.G. (2003). 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3, 330\u2013338.","journal-title":"Nat Rev Cancer"},{"key":"3437_CR28","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1158\/2326-6066.CIR-18-0126","volume":"7","author":"C Lu","year":"2019","unstructured":"Lu, C., Yang, D., Klement, J.D., Oh, I.K., Savage, N.M., Waller, J.L., Colby, A.H., Grinstaff, M.W., Oberlies, N.H., Pearce, C.J., et al. (2019). SUV39H1 represses the expression of cytotoxic T-lymphocyte effector genes to promote colon tumor immune evasion. Cancer Immunol Res 7, 414\u2013427.","journal-title":"Cancer Immunol Res"},{"key":"3437_CR29","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood.2024024861","volume":"145","author":"P Lu","year":"2025","unstructured":"Lu, P., Zhang, X., Yang, J., Li, J., Qiu, L., Gong, M., Wang, H., Chen, J., Liu, H., Xiong, M., et al. (2025). Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia. Blood 145, 1022\u20131033.","journal-title":"Blood"},{"key":"3437_CR30","doi-asserted-by":"publisher","first-page":"110129","DOI":"10.1016\/j.intimp.2023.110129","volume":"120","author":"AA Mathew","year":"2023","unstructured":"Mathew, A.A., Zakkariya, Z.T., Ashokan, A., Manohar, M., Keechilat, P., Nair, S.V., and Koyakutty, M. (2023). 5-FU mediated depletion of myeloid suppressor cells enhances T-cell infiltration and anti-tumor response in immunotherapy-resistant lung tumor. Int Immunopharmacol 120, 110129.","journal-title":"Int Immunopharmacol"},{"key":"3437_CR31","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","volume":"32","author":"DJ McGrail","year":"2021","unstructured":"McGrail, D.J., Pili\u00e9, P.G., Rashid, N.U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A.B., Lim, B., et al. (2021). High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol 32, 661\u2013672.","journal-title":"Ann Oncol"},{"key":"3437_CR32","doi-asserted-by":"publisher","first-page":"e2304319120","DOI":"10.1073\/pnas.2304319120","volume":"120","author":"G Micevic","year":"2023","unstructured":"Micevic, G., Daniels, A., Flem-Karlsen, K., Park, K., Talty, R., McGeary, M., Mirza, H., Blackburn, H.N., Sefik, E., Cheung, J.F., et al. (2023). IL-7R licenses a population of epigenetically poised memory CD8+ T cells with superior antitumor efficacy that are critical for melanoma memory. Proc Natl Acad Sci USA 120, e2304319120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3437_CR33","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller, B.C., Sen, D.R., Al Abosy, R., Bi, K., Virkud, Y.V., LaFleur, M.W., Yates, K.B., Lako, A., Felt, K., Naik, G.S., et al. (2019). Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol 20, 326\u2013336.","journal-title":"Nat Immunol"},{"key":"3437_CR34","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris, V.K., Kennedy, E.B., Baxter, N.N., Benson Iii, A.B., Cercek, A., Cho, M., Ciombor, K.K., Cremolini, C., Davis, A., Deming, D.A., et al. (2023). Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol 41, 678\u2013700.","journal-title":"J Clin Oncol"},{"key":"3437_CR35","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1084\/jem.188.11.2033","volume":"188","author":"M M\u00fcller","year":"1998","unstructured":"M\u00fcller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S.L., Galle, P.R., Stremmel, W., Oren, M., et al. (1998). p53 activates the CD95 (APO-1\/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 188, 2033\u20132045.","journal-title":"J Exp Med"},{"key":"3437_CR36","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1038\/s41591-024-03228-8","volume":"30","author":"BLZ Oh","year":"2024","unstructured":"Oh, B.L.Z., Shimasaki, N., Coustan-Smith, E., Chan, E., Poon, L., Lee, S.H.R., Yeap, F., Tan, L.K., Chai, L.Y.A., Le Bert, N., et al. (2024). Fratricide-resistant CD7-CAR T cells in T-ALL. Nat Med 30, 3687\u20133696.","journal-title":"Nat Med"},{"key":"3437_CR37","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","volume":"184","author":"K Pelka","year":"2021","unstructured":"Pelka, K., Hofree, M., Chen, J.H., Sarkizova, S., Pirl, J.D., Jorgji, V., Bejnood, A., Dionne, D., Ge, W.H., Xu, K.H., et al. (2021). Spatially organized multicellular immune hubs in human colorectal cancer. Cell 184, 4734\u20134752.e20.","journal-title":"Cell"},{"key":"3437_CR38","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nri3608","volume":"14","author":"LW Peterson","year":"2014","unstructured":"Peterson, L.W., and Artis, D. (2014). Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol 14, 141\u2013153.","journal-title":"Nat Rev Immunol"},{"key":"3437_CR39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","volume":"22","author":"M Philip","year":"2022","unstructured":"Philip, M., and Schietinger, A. (2022). CD8+ T cell differentiation and dysfunction in cancer. Nat Rev Immunol 22, 209\u2013223.","journal-title":"Nat Rev Immunol"},{"key":"3437_CR40","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/3877","volume":"20","author":"A Puel","year":"1998","unstructured":"Puel, A., Ziegler, S.F., Buckley, R.H., and Leonard, W.J. (1998). Defective IL7R expression in T\u2212B+NK+ severe combined immunodeficiency. Nat Genet 20, 394\u2013397.","journal-title":"Nat Genet"},{"key":"3437_CR41","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.cell.2023.02.021","volume":"186","author":"MK Rahim","year":"2023","unstructured":"Rahim, M.K., Okholm, T.L.H., Jones, K.B., McCarthy, E.E., Liu, C.C., Yee, J.L., Tamaki, S.J., Marquez, D.M., Tenvooren, I., Wai, K., et al. (2023). Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell 186, 1127\u20131143.e18.","journal-title":"Cell"},{"key":"3437_CR42","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert, C. (2020). A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun 11, 3801.","journal-title":"Nat Commun"},{"key":"3437_CR43","doi-asserted-by":"publisher","first-page":"1533857","DOI":"10.3389\/fimmu.2025.1533857","volume":"16","author":"X Ruan","year":"2025","unstructured":"Ruan, X., Wu, L., Tang, Z., Li, Y., Wang, J., Jiang, H., Zhang, L., Wang, S., Chen, Z., Yuan, C., et al. (2025). Two chemotherapeutic agents expand stem-like CD62L+CD8+ T cells in antitumor immune responses. Front Immunol 16, 1533857.","journal-title":"Front Immunol"},{"key":"3437_CR44","doi-asserted-by":"publisher","first-page":"2308097","DOI":"10.1080\/15384047.2024.2308097","volume":"25","author":"GS Santiago-S\u00e1nchez","year":"2024","unstructured":"Santiago-S\u00e1nchez, G.S., Fabian, K.P., and Hodge, J.W. (2024). A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance. Cancer Biol Ther 25, 2308097.","journal-title":"Cancer Biol Ther"},{"key":"3437_CR45","doi-asserted-by":"publisher","first-page":"e70208","DOI":"10.1111\/cbdd.70208","volume":"106","author":"MB Shahsavani","year":"2025","unstructured":"Shahsavani, M.B., Heidari, M., Yousefi, R., and Moosavi-Movahedi, A.A. (2025). Platinum-based chemotherapeutics in the modern era: from classical DNA-targeting mechanisms to next-generation innovations in cancer therapy. Chem Biol Drug Des 106, e70208.","journal-title":"Chem Biol Drug Des"},{"key":"3437_CR46","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/35074122","volume":"410","author":"V Shankaran","year":"2001","unstructured":"Shankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Old, L.J., and Schreiber, R.D. (2001). IFN\u03b3 and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107\u20131111.","journal-title":"Nature"},{"key":"3437_CR47","doi-asserted-by":"publisher","first-page":"113329","DOI":"10.1016\/j.intimp.2024.113329","volume":"143","author":"R Shi","year":"2024","unstructured":"Shi, R., Ran, L., Tian, Y., Guo, W., Zhao, L., Jin, S., Cheng, J., Zhang, Z., and Ma, Y. (2024). Prospects and challenges of neoantigen applications in oncology. Int Immunopharmacol 143, 113329.","journal-title":"Int Immunopharmacol"},{"key":"3437_CR48","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R.L., Miller, K.D., Fuchs, H.E., and Jemal, A. (2022). Cancer statistics, 2022. CA Cancer J Clin 72, 7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"3437_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1385\/IR:24:1:31","volume":"24","author":"R Stillwell","year":"2001","unstructured":"Stillwell, R., and Bierer, B.E. (2001). T cell signal transduction and the role of CD7 in costimulation. Immunol Res 24, 31\u201352.","journal-title":"Immunol Res"},{"key":"3437_CR50","doi-asserted-by":"publisher","first-page":"8052","DOI":"10.1074\/jbc.M610621200","volume":"282","author":"XX Sun","year":"2007","unstructured":"Sun, X.X., Dai, M.S., and Lu, H. (2007). 5-Fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J Biol Chem 282, 8052\u20138059.","journal-title":"J Biol Chem"},{"key":"3437_CR51","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1182\/blood-2006-06-027912","volume":"109","author":"L Swainson","year":"2007","unstructured":"Swainson, L., Kinet, S., Mongellaz, C., Sourisseau, M., Henriques, T., and Taylor, N. (2007). IL-7-induced proliferation of recent thymic emigrants requires activation of the PI3K pathway. Blood 109, 1034\u20131042.","journal-title":"Blood"},{"key":"3437_CR52","doi-asserted-by":"publisher","first-page":"e106065","DOI":"10.15252\/embj.2020106065","volume":"40","author":"J Tian","year":"2021","unstructured":"Tian, J., Zhang, D., Kurbatov, V., Wang, Q., Wang, Y., Fang, D., Wu, L., Bosenberg, M., Muzumdar, M.D., Khan, S., et al. (2021). 5-Fluorouracil efficacy requires antitumor immunity triggered by cancer-cell-intrinsic STING. EMBO J 40, e106065.","journal-title":"EMBO J"},{"key":"3437_CR53","first-page":"425","volume":"5","author":"D M Tillman","year":"1999","unstructured":"Tillman, D. M., Petak, I., and Houghton, J.A. (1999). A Fas-dependent component in 5-fluorouracil\/leucovorin-induced cytotoxicity in colon carcinoma cells. Clin Cancer Res 5, 425\u2013430.","journal-title":"Clin Cancer Res"},{"key":"3437_CR54","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.immuni.2024.11.026","volume":"58","author":"J Waibl Polania","year":"2025","unstructured":"Waibl Polania, J., Hoyt-Miggelbrink, A., Tomaszewski, W.H., Wachsmuth, L.P., Lorrey, S.J., Wilkinson, D.S., Lerner, E., Woroniecka, K., Finlay, J.B., Ayasoufi, K., et al. (2025). Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion. Immunity 58, 232\u2013246.e6.","journal-title":"Immunity"},{"key":"3437_CR55","doi-asserted-by":"publisher","first-page":"e00247","DOI":"10.1097\/BS9.0000000000000247","volume":"7","author":"L Wang","year":"2025","unstructured":"Wang, L., and Qiu, S. (2025). CD7 CAR-T therapy: current developments, improvements, and dilemmas. Blood Sci 7, e00247.","journal-title":"Blood Sci"},{"key":"3437_CR56","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","volume":"53","author":"SZ Wu","year":"2021","unstructured":"Wu, S.Z., Al-Eryani, G., Roden, D.L., Junankar, S., Harvey, K., Andersson, A., Thennavan, A., Wang, C., Torpy, J.R., Bartonicek, N., et al. (2021). A single-cell and spatially resolved atlas of human breast cancers. Nat Genet 53, 1334\u20131347.","journal-title":"Nat Genet"},{"key":"3437_CR57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., and Fu, L. (2023). Neoantigens: promising targets for cancer therapy. Sig Transduct Target Ther 8, 9.","journal-title":"Sig Transduct Target Ther"},{"key":"3437_CR58","doi-asserted-by":"publisher","first-page":"911663","DOI":"10.3389\/fphar.2022.911663","volume":"13","author":"JL Xu","year":"2022","unstructured":"Xu, J.L., Yuan, L., Hu, C., Weng, C.Y., Xu, H.D., Shi, Y.F., Huang, L., Ying, J.E., Xu, Z. Y., Qin, J.J., et al. (2022). Trametes robiniophila murr sensitizes gastric cancer cells to 5-fluorouracil by modulating tumor microenvironment. Front Pharmacol 13, 911663.","journal-title":"Front Pharmacol"},{"key":"3437_CR59","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.3390\/cancers15051563","volume":"15","author":"Y Yang","year":"2023","unstructured":"Yang, Y., Zhang, M., Zhang, Y., Liu, K., and Lu, C. (2023). 5-Fluorouracil suppresses colon tumor through activating the p53-Fas pathway to sensitize myeloid-derived suppressor cells to FasL+ cytotoxic T lymphocyte cytotoxicity. Cancers 15, 1563.","journal-title":"Cancers"},{"key":"3437_CR60","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost, K.E., Satpathy, A.T., Wells, D.K., Qi, Y., Wang, C., Kageyama, R., McNamara, K. L., Granja, J.M., Sarin, K.Y., Brown, R.A., et al. (2019). Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med 25, 1251\u20131259.","journal-title":"Nat Med"},{"key":"3437_CR61","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.3390\/biomedicines12122771","volume":"12","author":"LE Yu","year":"2024","unstructured":"Yu, L.E., Yang, W.C., and Liang, Y.C. (2024). Crosstalk within the intestinal epithelium: aspects of intestinal absorption, homeostasis, and immunity. Biomedicines 12, 2771.","journal-title":"Biomedicines"},{"key":"3437_CR62","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2020.03.048","volume":"181","author":"L Zhang","year":"2020","unstructured":"Zhang, L., Li, Z., Skrzypczynska, K.M., Fang, Q., Zhang, W., O\u2019Brien, S.A., He, Y., Wang, L., Zhang, Q., Kim, A., et al. (2020). Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell 181, 442\u2013459.e29.","journal-title":"Cell"},{"key":"3437_CR63","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41389-023-00492-0","volume":"12","author":"RW Zhou","year":"2023","unstructured":"Zhou, R.W., Harpaz, N., Itzkowitz, S.H., and Parsons, R.E. (2023). Molecular mechanisms in colitis-associated colorectal cancer. Oncogenesis 12, 48.","journal-title":"Oncogenesis"}],"container-title":["Science China Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-026-3437-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11427-026-3437-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11427-026-3437-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:02:30Z","timestamp":1792688550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11427-026-3437-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":63,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3437"],"URL":"https:\/\/doi.org\/10.1007\/s11427-026-3437-0","relation":{},"ISSN":["1674-7305","1869-1889"],"issn-type":[{"value":"1674-7305","type":"print"},{"value":"1869-1889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest. Studies with human specimens were approved by the Institutional Review Board of Tianjin Union Medical Center (Approval #0224-2021. Approval date: March 3rd, 2021) and the Institutional Review Board of Tianjin University (Approval #TJUE-2021-016. Approval date: March 1st, 2021).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance and ethics"}}]}}